Healthlynked CORP

HealthLynked Corp. announces the appointment of George O'Leary as Interim CFO and the elimination of the COO position, alongside a planned $7.5 million financing.

HealthLynked Corp. issued a $5.7 million senior secured convertible note to a trust controlled by its CEO, consolidating prior debt and unpaid compensation.

HealthLynked Corp. announced key executive and board appointments, including a new COO and two directors, to bolster its strategic initiatives for national expansion and a Nasdaq uplisting.

HealthLynked Corp. completed a 1-for-100 reverse stock split to enhance market positioning, attract institutional investors, and prepare for potential uplisting.

HealthLynked Corp. issued a warrant to purchase 1,353,356 shares and extended the maturity dates of existing notes payable to a trust controlled by its CEO, Dr. Michael Dent.

HealthLynked Corp. released its Annual Shareholder Letter, emphasizing product development, strategic partnerships, and a vision for future growth driven by AI and telemedicine.

HealthLynked reports a net loss of $1.62 million for Q1 2026 amid ongoing liquidity challenges and significant debt restructuring.

HealthLynked Corp. reported a narrower net loss in Q3 2025 due to aggressive cost-cutting, despite significant revenue declines across all divisions and ongoing substantial doubt about its ability to continue as a going concern.

HealthLynked Corp. reported a 40% reduction in net loss for Q2 2025, driven by aggressive cost-cutting, though liquidity remains a significant concern with a going concern warning.

HealthLynked Corp.'s Q1 2025 revenue decreased by 23% year-over-year, although the net loss was reduced due to cost-cutting measures.

HealthLynked Corp. experienced a significant decrease in revenue and a net loss in Q3 2024, primarily due to a decline in patient service revenue and an impairment charge related to its NCFM medical database.

HealthLynked Corp. reported a significant year-over-year revenue decrease and an increased net loss for the second quarter of 2024, primarily due to reduced patient service revenue and increased debt-related expenses.

HealthLynked Corp.'s 2024 annual report reveals a net loss, decreased revenue, and raises substantial doubt about the company's ability to continue as a going concern without additional funding.

HealthLynked Corp.'s 2023 annual report reveals a net loss of $1 million, a significant improvement from the previous year, but also raises concerns about the company's ability to continue as a going concern.

George O'Leary, Chief Financial Officer and a Director of HealthLynked Corp, received 35,000 shares of common stock on July 22, 2026.

HealthLynked Corp's CEO, Michael Dent, reports the acquisition of convertible notes through a trust.

Michael Dent, CEO of HealthLynked Corp, reports the acquisition of convertible notes through a trust.

Michael Dent, CEO of HealthLynked Corp, reports the acquisition of convertible notes through a trust.

Michael Dent, CEO of HealthLynked Corp, reports the acquisition of convertible notes through a trust and the expiration of warrants.

CEO Michael Dent reports the acquisition of convertible notes and warrants through a trust, signaling continued investment in HealthLynked Corp.

HealthLynked Corp. will implement a 100-for-1 reverse stock split to increase its per-share stock price and attract institutional investors, with the action expected to be effective around April 28, 2025.

HealthLynked Corp. has filed an amended S-1 registration statement for a $7 million public offering of common stock to fund operations and support a potential Nasdaq listing.

HealthLynked Corp. has filed an amendment to its S-1 registration statement for a $7 million public offering of common stock and a concurrent resale offering.